



SUVEN Life Sciences

Communication to investors

June 2010

28-Jul-10

2010-11 Q1 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

FINANCIAL QUICK VIEW

Quarter 1 – June 2010



- Growth in revenue 16.05%
- Growth in PAT 57.76%
- Growth in EBIDTA 2.25%
- Growth in Pre-R&D EBIDTA 8.84%
- Increase in R&D costs 13.16%
- R&D cost on revenue 21.16%


MAJOR PROFITABILITY RATIOS



	Q1 June 10	Q1 June 09
PAT to Income	9.49%	6.98%
EBIDTA to Income	12.55%	14.24%
Cash Flow to Income	13.19%	11.16%
Pre-R&D EBITDA to Income	33.71%	35.94%




INCOME COMPARISON






PROFIT COMPARISON






EBIDTA COMPARISON






R & D – EXPENDITURE






PRE-R&D EBIDTA





PRE-R&D CASHFLOW





Updates for the quarter

Suven Life Sciences Scientists presented data on the following molecules at International Conference on Alzheimer's Disease (ICAD) at Honolulu, Hawaii during July 10 - 15, 2010:

- ***SUVN-91052***: A potent and selective 5-HT₄ agonist for the treatment of Alzheimer's disease.
- ***SUVN-911***: A novel and selective $\alpha 4\beta 2$ agonist for the treatment of memory related disorders and depression.
- ***SUVN-90121***: A selective nicotinic acetylcholine receptor (nAChR) ligand for the treatment of cognitive impairment and depression.
- ***SUVN-91121***: A novel and selective H₃ antagonist for the improvement of memory related disorders.



Updates for the quarter

- Suven participated at **12th Annual C21 BioVentures™ (C21), at Napa, California, USA from May 25-27, 2010.**
- Mr.Venkat Jasti ,CEO of Suven has presented the company's corporate overview, business strategy, fund raising and partnering activity for their Phase 1 clinical candidate **SUVN-502 for cognition in Alzheimer's and Schizophrenia during the C21 BioVentures™ 2010** where the world's top notch investment professionals were present along with the most innovative companies decision makers.
- **Prof Syed E Hasnain has joined the Board of Suven Life Sciences as Additional Director w.e.f. 30th April 2010.**
- Prof. Syed E. Hasnain is currently the Vice Chancellor of the University of Hyderabad. Before he became the vice chancellor in Dec 2005, he was the first Director of CDFD at Hyderabad since 1999.



Updates On Patents

- June 16 2010
Suven Life Sciences secures Two (2) Product Patents from Japanese Patent Office (JPO) for their NCE's to treat Central Nervous System (CNS) disorders
- May 12 2010
Suven Life Sciences secures 3rd Canadian and 6th Eurasian Patent for their NCE
- Apr 28 2010
Suven Life Sciences secures Product Patents from India and New Zealand
- Apr 22 2010
Suven Life Sciences secures Three Australian Patents on NCEs
- Apr 12 2010
Suven Life Sciences secures First Product Patent from Japanese Patent Office (JPO) for their NCE to treat Central Nervous System (CNS) disorders



Updates For Future

- *Suven will be participating in the following conferences during 2010*

240th ACS National Meeting & Exposition

Boston, MA, August 22 - 26, 2010

- ***Society for Neuroscience Annual Meeting (Neuroscience 2010)***

San Diego, CA, November 13 -17, 2010

- ***American Association of Pharmaceutical Scientists (AAPS) Annual Meeting & Exposition 2010***

New Orleans, LA, November 15 - 17, 2010



AGM updates

The following are the updates of the AGM held on 27 July 2010:

- Payment of dividend of Rs 0.25 (25%) per equity share of Rs 1 each.
- Approved and authorized the Board to raise funds not exceeding US\$ 50 million through issue of ADR/GDR/FCCB or other securities through international or domestic offerings.



SUVEN an end to end bio-pharmaceutical solutions company

Drug Discovery



Drug Discovery & Development Support Services (DDDSS)

Contract Research And Manufacturing Services (CRAMS)

Collaborative Research Partner (CRP) ...
Seamless transition

2010-11 Q1 results